NurExone Announces Corporate Updates
Globenewswire·2026-03-11 12:28
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement ClosingTORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and the closing ...